Cingulate Reports Third Quarter 2024 Financial ResultsReflecting 19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
CING Stock | USD 4.36 0.16 3.81% |
Roughly 55% of Cingulate's stockholders are presently thinking to get in. The analysis of the overall investor sentiment regarding Cingulate suggests that some traders are interested. The current market sentiment, together with Cingulate's historical and current headlines, can help investors time the market. In addition, many technical investors use Cingulate stock news signals to limit their universe of possible portfolio assets.
Cingulate |
On Target for Mid-2025 New Drug Application Submission of lead ADHD asset CTx-1301KANSAS CITY, Kan., Nov. 07, 2024 -- Cingulate Inc. , a biopharmaceutical company utilizing its proprietary Precision Timed Release drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended September 30, 2024, and provided a clinical and business update. T
Read at finance.yahoo.com
Cingulate Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Cingulate can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cingulate Fundamental Analysis
We analyze Cingulate's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cingulate using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cingulate based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Cingulate is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Cingulate Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cingulate stock to make a market-neutral strategy. Peer analysis of Cingulate could also be used in its relative valuation, which is a method of valuing Cingulate by comparing valuation metrics with similar companies.
Peers
Cingulate Related Equities
ANTX | AN2 Therapeutics | 21.90 | ||||
MNPR | Monopar Therapeutics | 8.84 | ||||
GNLX | Genelux Common | 8.03 | ||||
IKT | Inhibikase Therapeutics | 6.96 | ||||
ADAG | Adagene | 1.30 | ||||
PMVP | Pmv Pharmaceuticals | 1.25 | ||||
RZLT | Rezolute | 1.00 | ||||
SNTI | Senti Biosciences | 0.93 | ||||
ACRV | Acrivon Therapeutics, | 0.80 | ||||
ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
AVTE | Aerovate Therapeutics | 0.38 | ||||
DYAI | Dyadic International | 8.56 |
Complementary Tools for Cingulate Stock analysis
When running Cingulate's price analysis, check to measure Cingulate's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cingulate is operating at the current time. Most of Cingulate's value examination focuses on studying past and present price action to predict the probability of Cingulate's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cingulate's price. Additionally, you may evaluate how the addition of Cingulate to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |